FORTY FORT, PA -- Two Geisinger Health System researchers have been invited to participate in the prestigious 2015 FH (familial hypercholesterolemia) Foundation Global Summit, Sept. 24-25, in Pasadena, Calif. The annual invitation-only event is dedicated to the science and treatment of FH.
Michael Murray (left), M.D., director of clinical genomics in Geisinger’s Genomic Medicine Institute, and Caroline Graham (right), CRNP, advanced practice provider in the Richard & Marion Pearsall Heart Hospital at Geisinger Wyoming Valley Medical Center, have been invited. Dr. Murray will participate in an experts’ debate on how to find and manage FH patients at a healthcare system level.
Familial hypercholesterolemia is a largely underdiagnosed, life threatening and treatable genetic disorder that can cause heart attack and stroke at an early age.
The annual invitation-only summit is a global gathering of medical experts, patient advocacy organizations, health care providers and individuals with FH. The two-day event features presentations that provide a platform to share insights and practices for improved awareness, diagnosis and treatment of FH.
This year’s theme, “FH at the Crossroads: New Data on Prevalence & Novel Strategies for Prevention,” will cover a wide variety of topics and solutions, including insights into the prevalence and characteristics of the FH population, optimizing patient care and engagement, and strategies for early diagnosis and prevention.
“The FH Global Summit is a phenomenal opportunity for the Geisinger Health System and the Pearsall Heart Hospital,” Graham said. “Ultimately, this will benefit my patients and the patients I will soon meet.”
Geisinger’s GenomeFIRST program is expected to deliver results back to several hundred patients with FH over the next two years and will help build new models for diagnosis and treatment of this life-threatening disease. Dr. Murray and NP Graham were among the faculty that highlighted this plan in Geisinger’s inaugural GenomeFIRST symposium, “Changing the Lives of Patients with Familial Hypercholesterolemia,” which was held in May.
One of the nation’s most innovative health services organizations, Geisinger serves more than 1.5 million patients in Pennsylvania and New Jersey. The system includes 13 hospital campuses, a nearly 600,000-member health plan, two research centers and the Geisinger Commonwealth School of Medicine. Geisinger is known for its focus on caring and innovative programs including the ProvenCare® best-practice approach to maximize quality, safety and value; ProvenHealth Navigator® advanced medical home; Springboard Health® population health program to improve the health of an entire community; ProvenExperience™ to provide refunds to patients unhappy with their care experience; and Geisinger’s MyCode® Community Health Initiative, the largest healthcare system-based precision health project in the world. With more than 215,000 volunteer participants enrolled, MyCode is conducting extensive research and returning medically actionable results to participants. A physician-led organization, with approximately 32,000 employees and more than 1,800 employed physicians, Geisinger leverages an estimated $12.7 billion positive annual impact on the Pennsylvania and New Jersey economies. Repeatedly recognized nationally for integration, quality and service, Geisinger has a long-standing commitment to patient care, medical education, research and community service. For more information, visit www.geisinger.org, or connect with us on Facebook, Instagram, LinkedIn and Twitter.